Please wait...

Quick Stats

Offers Claimed:


Downloaded Today:


Marplan Prescription
view details
Generic Name: isocarboxazid (eye so kar BOX a zid)
Brand Name: Marplan
Physician reviewed Marplan patient information - includes Marplan description, dosage and directions.
Generic Name: isocarboxazid (eye so kar BOX a zid)
Brand Name: Marplan
Physician reviewed Marplan patient information - includes Marplan description, dosage and directions.
  • Select Your Prescription Settings
  • X
30 tablets of Marplan 40 mg
  • Select Your Prescription Settings
  • X

Quick Stats

Offers Claimed: 143

Downloaded Today: 174

Set your location
for drug prices near you

Marplan Coupons & Prices

Set your location
for drug prices near you

Enter your ZIP Code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Marplan Drug Information:

Marplan is a monoamine oxidase inhibitor (MAOI) that works by increasing the levels of certain chemicals in the brain. Marplan is used to treat symptoms of depression that may include anxiety, panic, or phobias. This medicine is usually given after other antidepressants have been tried without successful treatment of symptoms. Marplan may also be used for purposes not listed in this medication guide. There are many other medicines that can cause serious medical problems or death if you take them together with Marplan. Before taking this medicine, tell your doctor about all medicines you have used within the past 5 weeks. Learn more

Marplan Side Effects

Note: This document contains side effect information about isocarboxazid. Some of the dosage forms listed on this page may not apply to the brand name Marplan.

In Summary

Common side effects of Marplan include: dizziness and headache. Other side effects include: suicidal ideation, suicidal tendencies, drowsiness, sleep disorder, tremor, nausea, and orthostatic hypotension. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to isocarboxazid: oral tablet


Oral route (Tablet)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients.

Along with its needed effects, isocarboxazid (the active ingredient contained in Marplan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking isocarboxazid:

Less common

  • Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chills
  • cold sweats
  • confusion
  • difficult urination
  • dizziness, faintness, or lightheadedness when getting up from lying or sitting position
  • fainting
  • fast, irregular, pounding, or racing heartbeat or pulse
  • fear or nervousness
  • heavy feeling
  • increased need to urinate
  • passing urine more often
  • restlessness
  • shakiness in the legs, arms, hands, or feet
  • sudden jerky movements of the body
  • sweating
  • trembling or shaking of the hands or feet
  • trouble sitting still

Incidence not known

  • Agitation
  • burning while urinating
  • change in consciousness
  • decrease in frequency of urination
  • decrease in urine volume
  • decreased urine output
  • depression
  • difficulty in passing urine (dribbling)
  • dizziness
  • false or unusual sense of well-being
  • headache
  • hostility
  • irritability
  • loss of bladder control
  • loss of consciousness
  • muscle twitching
  • nausea
  • need to keep moving
  • numbness or tingling of the hands, feet, or face
  • rapid weight gain
  • seeing, hearing, or feeling things that are not there
  • seizures
  • shakiness and unsteady walk
  • stupor
  • swelling of the face, ankles, or hands
  • unsteadiness, trembling, or other problems with muscle control or coordination
  • unusual tiredness or weakness

Some side effects of isocarboxazid may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Constipation
  • dry mouth

Less common

  • Decreased interest in sexual intercourse
  • drowsiness
  • inability to have or keep an erection
  • loss in sexual ability, desire, drive, or performance
  • relaxed and calm
  • sleepiness
  • sleeplessness
  • trouble sleeping
  • unable to sleep
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness

Incidence not known

  • Black tongue
  • blurred vision
  • change in vision
  • impaired vision
  • increased sensitivity of the skin to sunlight
  • itching
  • raised, dark red, wart-like spots on the skin, especially when used on the face
  • redness or other discoloration of the skin
  • severe sunburn
  • skin rash

For Healthcare Professionals

Applies to isocarboxazid: oral tablet


Common (1% to 10%): Orthostatic hypotension, palpitations

Frequency not reported: Disturbances in cardiac rhythm, peripheral edema

Orthostatic hypotension, disturbances in cardiac rhythm, and/or peripheral edema may be controlled by reducing the dose.

Nervous system

Dizziness and/or drowsiness may be controlled by reducing the dose.

Very common (10% or more): Dizziness (up to 29%), headache (up to 15%)

Common (1% to 10%): Drowsy/drowsiness, forgetful, hyperactive, lethargy, myoclonic jerks, paresthesia, sedation, syncope, tremor

Frequency not reported: Hyperreflexia, mild headache, overactivity, peripheral neuritis

Postmarketing reports: Akathisia, ataxia, coma, neuritis


Common (1% to 10%): Constipation, diarrhea, dry mouth, nausea

Frequency not reported: Vomiting

Postmarketing reports: Black tongue

Constipation, dry mouth, nausea, and/or vomiting may be controlled by reducing the dose.


Frequency not reported: Blurred vision

Postmarketing reports: Toxic amblyopia

Blurred vision may be controlled by reducing the dose.

Toxic amblyopia was reported in a patient with schizophrenia who received this drug for approximately 1 year; however, no causal relationship to this drug was established.


Frequency not reported: Muscle tremor


Common (1% to 10%): Impotence, urinary frequency, urinary hesitancy

Frequency not reported: Difficulty in micturition, impairment of erection and ejaculation

Postmarketing reports: Dysuria, incontinence, sexual disturbances, urinary retention


The most common adverse events were dizziness, headache, nausea, and dry mouth.


Postmarketing reports: Impaired water secretion compatible with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)


Common (1% to 10%): Sweating

Frequency not reported: Skin rashes

Postmarketing reports: Photosensitivity, spider telangiectases


Insomnia may be controlled by reducing the dose.

Hallucinations have been reported with high doses, but have disappeared with dose reduction or discontinuation of therapy.

Common (1% to 10%): Anxiety, insomnia, sleep disturbance

Frequency not reported: Agitation, behavioral changes, confusion, suicidal behavior, suicidal ideation

Postmarketing reports: Euphoria, hallucinations


Common (1% to 10%): Chills, heavy feeling

Frequency not reported: Fatigue, weakness

Fatigue and/or weakness may be controlled by reducing the dose.


Rare (less than 0.1%): Blood dyscrasias, granulocytopenia, purpura

Postmarketing reports: Hematologic changes


Frequency not reported: Increased appetite, weight gain

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.

Source: Drugs.com Marplan (www.drugs.com/mtm/marplan.html).